FDA OKs expanded label for Heron’s Cinvanti

Heron Therapeutics (NASDAQ:HRTX) is up 4% premarket on light volume in response to the FDA nod for a 130 mg single-dose IV regimen for Cinvanti (aprepitant) for patients receiving moderately emetogenic (nausea and vomiting-inducing) chemo.
https://seekingalpha.com/news/3507730-fda-oks-expanded-label-herons-cinvanti-shares-ahead-4-percent-premarket